Immunic Inc IMUX

NAS: IMUX | ISIN: US4525EP1011   30/04/2025
0,990 USD (-22,65%)
(-22,65%)   30/04/2025

30 april 2025 · Immunic Announces Vidofludimus Calcium Reduced Risk of Disability Worsening by 30% in Primary Progressive Multiple Sclerosis Patients from Phase 2 CALLIPER Trial · Persbericht

10 april 2025 · Immunic, Inc. Announces Closing of $5.1 Million Registered Direct Offering, Led by Aberdeen Investments · Persbericht

9 april 2025 · Immunic, Inc. Announces Pricing of $5.1 Million Registered Direct Offering, Led by Aberdeen Investments · Persbericht

1 april 2025 · Immunic, Inc. to Participate in Scientific and Industry Conferences in April · Persbericht

3 maart 2025 · Immunic to Participate in Scientific and Investor Conferences in March · Persbericht

4 september 2024 · Immunic Announces First Patient Enrolled in Investigator-Sponsored Phase 2 Clinical Trial of Vidofludimus Calcium in Patients with Post COVID Syndrome · Persbericht

28 augustus 2024 · Immunic to Host Multiple Sclerosis R&D Day and Participate in Scientific and Investor Conferences in September · Persbericht

8 augustus 2024 · Immunic, Inc. Reports Second Quarter 2024 Financial Results and Provides Corporate Update · Persbericht

1 augustus 2024 · Immunic, Inc. to Announce Financial Results for the Second Quarter Ended June 30, 2024, and Provide Corporate Update · Persbericht

24 juli 2024 · Immunic, Inc. Strengthens Its Board of Directors with the Appointment of Experienced Pharmaceutical Executive Simona Skerjanec · Persbericht

9 juli 2024 · Immunic Appoints Jason Tardio as Chief Operating Officer and President · Persbericht

28 mei 2024 · Immunic to Participate in Industry and Scientific Conferences in June · Persbericht

8 mei 2024 · Immunic, Inc. Reports First Quarter 2024 Financial Results and Provides Corporate Update · Persbericht

6 mei 2024 · Immunic to Participate in Investor and Scientific Conferences in May · Persbericht

1 mei 2024 · Immunic, Inc. to Announce Financial Results for the First Quarter Ended March 31, 2024, and Provide Corporate Update · Persbericht

30 april 2024 · Immunic Announces Publication of Extended Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis in the Peer Reviewed Journal, Neurology® Neuroimmunology & Neuroinflammation · Persbericht

4 april 2024 · Immunic to Host MS R&D Day and Participate in Investor Conferences in April · Persbericht

20 maart 2024 · Immunic Receives Notice of Allowance for Composition-of-Matter Patent of a Specific Polymorph of Vidofludimus Calcium in the United States · Persbericht

7 maart 2024 · Immunic to Participate in Investor and Scientific Conferences in March · Persbericht

29 februari 2024 · Immunic Presents Data From Phase 2 CALLIPER and CALVID-1 Trials of Vidofludimus Calcium at the ACTRIMS Forum 2024 · Persbericht

Mijn selecties